Titan Pharmaceuticals, Inc. (OTCBB:TTNP) Pushed Down by Panicky Sellers

Titan Pharmaceuticals, Inc. (OTCBB:TTNP) broke a five-day buying streak, as the company struggles to either make a big climb or retreat to its lower levels. On Tuesday, TTNP lost more than 7% to stand at $1.07, on dollar volumes of above $5 million.

The company was supposed to give a written update for filing a set of documents required to set up an FDA meeting in November. But no such PR piece appeared, and that may have caused concern.

TTNP is also not promoted, and while there is talk of prices reaching as high as $10, the ticker could not keep or improve the $1.16 levels. Investors’ opinions are disparate, some pointing toward the possibility that TTNP is still nothing more than a quick day trade. And TTNP is indeed volatile, with a somehow wide daily range.

But in case the fully-researched anti-addiction therapy gets approved, TTNP would receive a major boost from patent revenues, which so far came in only with an $18 million preliminary payment, awaiting a further $50 million upon approval, and awaiting further royalties. Probably the TTNP shares should move to reflect that value. Now, TTNP still has a long time to make the week memorable by bridging the gap from May.

TTNP is rising among a group of several pharmaceutical tickers that exhibit great value and move without the boost from a promotion. Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a well-developed pharmaceutical company, aims to repeat its peaks, as it grew again to 14 cents on dollar volumes above $818,000.

And while at a lower price range, Advanced Cell Technology, Inc. (OTCBB:ACTC) has been making a recovery, in the last few days standing more stably in the 7-cents range. ACTC is making bolder claims based on stem cells, and so far has yet to offer finished and accepted therapies. Still, the company of Dr. Robert Lanza fame is a staple among the most actively traded penny stocks.

In the case of TTNP, panicky sellers could do much worse, especially with a lack of good news. Still, the FDA meeting in mid-November will be the event that can ensure more days of good investor interest. It is best to decide on your preferred time frame for TTNP and avoid investing if you could be hurt by the volatility that often accompanies this ticker.